Pharmaceuticals company Senores Pharmaceuticals announced Q3FY26 results Income: Rs 175 crore during Q3FY26, change 64%. EBITDA: Rs 54 crore during Q3FY26, change 86%. PAT: Rs 34 crore during Q3FY26, change 105%. Swapnil Shah, Managing Director, Senores Pharmaceuticals, said: “Continuing our strong momentum, we delivered a robust performance in Q3FY26, with Revenue growing by 64% and Profit after Tax growing by 86% YoY. In the Regulated Markets, we launched two new ANDAs with 3 strengths during the quarter. We have 28 approved ANDAs available for launch. Additionally, we have 22 more molecules, involving 50+ strengths, at different stages of development. This gives us a healthy pipeline of products which are expected to be rolled out over the coming quarters. We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharma. We have completed acquisition of 75% stake, with the balance 25% expected to be completed by Q2FY27. The integration and scale-up of the Apnar Pharma business is happening faster than expected. The acquisition enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO-CMO opportunities, positioning Senores for sustained growth. Our Emerging Markets product portfolio continued to expand. With the shift towards niche products, we are now at mid-teens EBITDA Margin. We achieved our highest-ever quarterly Revenue and EBITDA in Emerging Markets in Q3FY26. Importantly, the business is now cash flow positive. The Branded Generics business is seeing significant growth, with revenue growing more than six-fold YoY in Q3FY26. Strong product acceptance and customer adoption are driving this momentum. We are now approved and supplying to multiple large hospital chains across India. All in all, we have delivered a strong performance in the quarter and nine-months and remain on track to deliver on our full year guidance. We will continue to drive the business on 4 key pillars – (i) Expansion of the ANDA Portfolio in Regulated Markets; (ii) Steady Scale-up of the CDMO/CMO Segment in Regulated Markets; (iii) Portfolio Expansion and Profitability Improvement in Emerging Markets; and (iv) Scale-up of Branded Generics business in India.” Result PDF